BRVE (Braveheart Bio) Dividend Payout Ratio: 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BRVE Braveheart Bio Inc BRVE
8 GF Score
Price $31.93
View Full Analysis

What is Braveheart Bio Dividend Payout Ratio?

Braveheart Bio BRVE -2.72% 8 Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus rates BRVE with a GF Score™ of 8/100.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Braveheart Bio's Dividend Payout Ratio for the months ended in Dec. 2025 was 0.00.

The historical rank and industry rank for Braveheart Bio's Dividend Payout Ratio or its related term are showing as below:


BRVE's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.445
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-08-08), the Dividend Yield % of Braveheart Bio is 0.00%.

Braveheart Bio's Dividends per Share for the months ended in Dec. 2025 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Braveheart Bio (NAS:BRVE) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Braveheart Bio Dividend Payout Ratio Related Terms

Braveheart Bio Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for Braveheart Bio's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Braveheart Bio Dividend Payout Ratio Chart

Braveheart Bio Annual Data
Trend Dec25
Dividend Payout Ratio
0.00

Braveheart Bio Semi-Annual Data
Dec25
Dividend Payout Ratio 0.00

BRVE vs : Dividend Payout Ratio Comparison

For the Biotechnology subindustry, Braveheart Bio's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Braveheart Bio Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Braveheart Bio's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Braveheart Bio's Dividend Payout Ratio falls into.


BRVE
8GF Score
Braveheart Bio Inc BRVE
Dividend Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Braveheart Bio Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Braveheart Bio's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2025 )/ EPS without NRI (A: Dec. 2025 )
=0/ -0.305
=N/A

Braveheart Bio's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2025 )/ EPS without NRI (Q: Dec. 2025 )
=0/ -0.305
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
Braveheart Bio (BRVE) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Braveheart Bio and its competitors.
Is Braveheart Bio's Dividend Payout Ratio too high?
Braveheart Bio's current Dividend Payout Ratio is 0.00. Overall, Braveheart Bio has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Braveheart Bio's Dividend Payout Ratio compare to ?
Braveheart Bio's Dividend Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median Dividend Payout Ratio is 0.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.45, based on 130 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Braveheart Bio and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Braveheart Bio's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Braveheart Bio stock overvalued right now?
Braveheart Bio (BRVE) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. Braveheart Bio's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Braveheart Bio (BRVE), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Braveheart Bio Business Description

Comparable Companies
Address One Letterman Drive, Suite A4-300, Building A, San Francisco, CA, USA, 94129
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
8GF Score

Get the complete analysis for BRVE

Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.93
Price